Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker OLMA
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Oct 16, 2026 | SCHEDULE 13D/A (amended) | OLMA Olema Oncology, Inc. | Hrustanovic Gorjan | 183,645 | 0.2% | SCHEDULE 13D/A ↗ |
| Oct 16, 2026 | SCHEDULE 13D/A (amended) | OLMA Olema Oncology, Inc. | Mark N. Lampert | 8.94M | 9.8% | SCHEDULE 13D/A ↗ |
| Oct 16, 2026 | SCHEDULE 13D/A (amended) | OLMA Olema Oncology, Inc. | BVF Inc/Il | 8.94M | 9.8% | SCHEDULE 13D/A ↗ |
| Oct 16, 2026 | SCHEDULE 13D/A (amended) | OLMA Olema Oncology, Inc. | BVF Partners L P/Il | 8.94M | 9.8% | SCHEDULE 13D/A ↗ |
| Oct 16, 2026 | SCHEDULE 13D/A (amended) | OLMA Olema Oncology, Inc. | BVF GP Holdings LLC | 8.30M | 9.1% | SCHEDULE 13D/A ↗ |
| Oct 16, 2026 | SCHEDULE 13D/A (amended) | OLMA Olema Oncology, Inc. | BVF Partners OS Ltd. | 347,970 | 0.4% | SCHEDULE 13D/A ↗ |
| Oct 16, 2026 | SCHEDULE 13D/A (amended) | OLMA Olema Oncology, Inc. | Biotechnology Value Trading Fund OS LP | 347,970 | 0.4% | SCHEDULE 13D/A ↗ |
| Oct 16, 2026 | SCHEDULE 13D/A (amended) | OLMA Olema Oncology, Inc. | BVF II GP LLC | 2.36M | 2.7% | SCHEDULE 13D/A ↗ |
| Oct 16, 2026 | SCHEDULE 13D/A (amended) | OLMA Olema Oncology, Inc. | Biotechnology Value Fund II LP | 2.36M | 2.7% | SCHEDULE 13D/A ↗ |
| Oct 16, 2026 | SCHEDULE 13D/A (amended) | OLMA Olema Oncology, Inc. | BVF I GP LLC | 5.95M | 6.6% | SCHEDULE 13D/A ↗ |
| Oct 16, 2026 | SCHEDULE 13D/A (amended) | OLMA Olema Oncology, Inc. | Biotechnology Value Fund L P | 5.95M | 6.6% | SCHEDULE 13D/A ↗ |
| Aug 6, 2026 | SCHEDULE 13G/A (amended) | OLMA Olema Oncology, Inc. | Abigail P. Johnson | 12.08M | 13.8% | SCHEDULE 13G/A ↗ |
| Aug 6, 2026 | SCHEDULE 13G/A (amended) | OLMA Olema Oncology, Inc. | FMR LLC | 12.08M | 13.8% | SCHEDULE 13G/A ↗ |
| Jul 29, 2026 | SCHEDULE 13G/A (amended) | OLMA Olema Oncology, Inc. | BlackRock, Inc. | 6.24M | 7.1% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | OLMA Olema Oncology, Inc. | Janus Henderson Group PLC | 7.11M | 8.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | OLMA Olema Oncology, Inc. | Bain Capital Life Sciences Opportunities IV, L.P. | 7.47M | 8.2% | SCHEDULE 13G/A ↗ |
| Mar 20, 2026 | SCHEDULE 13G | OLMA Olema Oncology, Inc. | Raymond Debbane | 4.46M | 5.1% | SCHEDULE 13G ↗ |
| Mar 20, 2026 | SCHEDULE 13G | OLMA Olema Oncology, Inc. | Ulys, L.L.C. | 563,449 | 0.6% | SCHEDULE 13G ↗ |
| Mar 20, 2026 | SCHEDULE 13G | OLMA Olema Oncology, Inc. | Avicenna Life Sci Master GP LLC | 563,449 | 0.6% | SCHEDULE 13G ↗ |
| Mar 20, 2026 | SCHEDULE 13G | OLMA Olema Oncology, Inc. | Avicenna Life Sci Master Fund LP | 563,449 | 0.6% | SCHEDULE 13G ↗ |
| Mar 20, 2026 | SCHEDULE 13G | OLMA Olema Oncology, Inc. | Siren, L.L.C. | 3.90M | 4.5% | SCHEDULE 13G ↗ |
| Mar 20, 2026 | SCHEDULE 13G | OLMA Olema Oncology, Inc. | Invus Global Management, LLC | 3.90M | 4.5% | SCHEDULE 13G ↗ |
| Mar 20, 2026 | SCHEDULE 13G | OLMA Olema Oncology, Inc. | Invus Public Equities Advisors, LLC | 3.90M | 4.5% | SCHEDULE 13G ↗ |
| Mar 20, 2026 | SCHEDULE 13G | OLMA Olema Oncology, Inc. | Invus Public Equities, L.P. | 3.90M | 4.5% | SCHEDULE 13G ↗ |
| Mar 6, 2026 | SCHEDULE 13G/A (amended) | OLMA Olema Oncology, Inc. | Abigail P. Johnson | 10.00M | 12.5% | SCHEDULE 13G/A ↗ |
| Mar 6, 2026 | SCHEDULE 13G/A (amended) | OLMA Olema Oncology, Inc. | FMR LLC | 10.00M | 12.5% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | OLMA Olema Oncology, Inc. | Janus Henderson Group PLC | 6.71M | 8.4% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | OLMA Olema Oncology, Inc. | Bain Capital Life Sciences Opportunities IV, L.P. | 8.51M | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | OLMA Olema Oncology, Inc. | David Kroin | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | OLMA Olema Oncology, Inc. | Deep Track Biotechnology Master Fund, Ltd. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | OLMA Olema Oncology, Inc. | Deep Track Capital, LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 5, 2026 | SCHEDULE 13G | OLMA Olema Oncology, Inc. | Abigail P. Johnson | 5.02M | 6.3% | SCHEDULE 13G ↗ |
| Feb 5, 2026 | SCHEDULE 13G | OLMA Olema Oncology, Inc. | FMR LLC | 5.02M | 6.3% | SCHEDULE 13G ↗ |
| Nov 14, 2025 | SCHEDULE 13G | OLMA Olema Oncology, Inc. | Janus Henderson Group PLC | 3.59M | 5.2% | SCHEDULE 13G ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | OLMA Olema Oncology, Inc. | David Kroin | 3.44M | 5.0% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | OLMA Olema Oncology, Inc. | Deep Track Biotechnology Master Fund, Ltd. | 3.44M | 5.0% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | OLMA Olema Oncology, Inc. | Deep Track Capital, LP | 3.44M | 5.0% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | OLMA Olema Oncology, Inc. | Bain Capital Life Sciences Opportunities IV, L.P. | 6.84M | 10.0% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | OLMA Olema Oncology, Inc. | Steven A. Cohen | 1.54M | 2.3% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | OLMA Olema Oncology, Inc. | Point72 Capital Advisors, Inc. | 1.54M | 2.3% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | OLMA Olema Oncology, Inc. | Point72 Asset Management, L.P. | 1.54M | 2.3% | SCHEDULE 13G/A ↗ |
| May 13, 2025 | SCHEDULE 13D/A (amended) | OLMA Olema Oncology, Inc. | Logos GP LLC | 2.51M | 3.7% | SCHEDULE 13D/A ↗ |
| May 13, 2025 | SCHEDULE 13D/A (amended) | OLMA Olema Oncology, Inc. | Logos Opportunities GP LLC | 708,114 | 1.0% | SCHEDULE 13D/A ↗ |
| May 13, 2025 | SCHEDULE 13D/A (amended) | OLMA Olema Oncology, Inc. | Graham Walmsley | 3.21M | 4.7% | SCHEDULE 13D/A ↗ |
| May 13, 2025 | SCHEDULE 13D/A (amended) | OLMA Olema Oncology, Inc. | William Arsani | 3.21M | 4.7% | SCHEDULE 13D/A ↗ |
| May 13, 2025 | SCHEDULE 13D/A (amended) | OLMA Olema Oncology, Inc. | Logos Global Management GP LLC | 3.21M | 4.7% | SCHEDULE 13D/A ↗ |
| May 13, 2025 | SCHEDULE 13D/A (amended) | OLMA Olema Oncology, Inc. | Logos Global Management LP | 3.21M | 4.7% | SCHEDULE 13D/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | OLMA Olema Oncology, Inc. | Paradigm BioCapital International Fund Ltd. | 6.78M | 9.1% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | OLMA Olema Oncology, Inc. | Senai Asefaw, M.D. | 7.43M | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | OLMA Olema Oncology, Inc. | Paradigm BioCapital Advisors GP LLC | 7.43M | 10.0% | SCHEDULE 13G/A ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:30 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances